KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Bristol Myers Squibb (BMY) Asset Utilization Ratio (2009 - 2026)

Bristol Myers Squibb (BMY) reported Asset Utilization Ratio of 0.55 for Q1 2026, up 6.69% year-over-year from 0.51 in Q1 2025, and up 6.53% on a QoQ basis from 0.52 in Q4 2025.

Bristol Myers Squibb (BMY) has 17 years of Asset Utilization Ratio data on file, last reported at 0.55 in Q1 2026.

  • Quarterly Asset Utilization Ratio rose 6.69% year-over-year to 0.55 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 0.55 (up 6.69% YoY) and the FY2025 annual result came in at 0.53, up 2.58% from the prior year.
  • Asset Utilization Ratio improved to 0.55 in Q1 2026 per BMY's latest filing, from 0.52 in the prior quarter.
  • Across five years, Asset Utilization Ratio topped out at 0.55 in Q1 2026 and bottomed at 0.44 in Q1 2022.
  • The 5-year median for Asset Utilization Ratio is 0.48 (2023), against an average of 0.49.
  • The widest annual swing landed in 2022, when Asset Utilization Ratio climbed 19.29%; it then declined 2.26% in 2024.
  • Tracing BMY's Asset Utilization Ratio over 5 years: stood at 0.47 in 2022, then rose by 2.0% to 0.48 in 2023, then rose by 7.4% to 0.52 in 2024, then fell by 0.57% to 0.52 in 2025, then rose by 6.53% to 0.55 in 2026.
  • Per Business Quant, the three latest BMY Asset Utilization Ratio figures stand at 0.55 (Q1 2026), 0.52 (Q4 2025), and 0.5 (Q3 2025).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Asset Util. (Qtr)
1 Novartis Ag 107,124,802.25 Bn 107,124,802.25 Bn - -
2 Eli Lilly 969.00 Bn 963.72 Bn 16.22 Bn 0.63
3 Johnson & Johnson 539.46 Bn 517.41 Bn 15.96 Bn 0.48
4 AbbVie 376.92 Bn 367.57 Bn 10.78 Bn 0.46
5 Merck 285.00 Bn 279.35 Bn 12.09 Bn 0.50
6 Amgen 177.58 Bn 165.55 Bn 5.87 Bn 0.41
7 Gilead Sciences 163.22 Bn 155.50 Bn 5.52 Bn 0.52
8 Pfizer 145.86 Bn 133.09 Bn -1.21 Bn 0.12
9 Bristol Myers Squibb 111.90 Bn 101.44 Bn 8.07 Bn 0.55
10 Gsk 88.34 Bn 83.66 Bn - -

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 0.55
Dec 31, 2025 0.52
Sep 30, 2025 0.50
Jun 30, 2025 0.51
Mar 31, 2025 0.51
Dec 31, 2024 0.52
Sep 30, 2024 0.50
Jun 30, 2024 0.48
Mar 31, 2024 0.47
Dec 31, 2023 0.48
Sep 30, 2023 0.49
Jun 30, 2023 0.48
Mar 31, 2023 0.48
Dec 31, 2022 0.47
Sep 30, 2022 0.47
Jun 30, 2022 0.46
Mar 31, 2022 0.44
Dec 31, 2021 0.42
Sep 30, 2021 0.41
Jun 30, 2021 0.40
Mar 31, 2021 0.37
Dec 31, 2020 0.35
Sep 30, 2020 0.31
Jun 30, 2020 0.27
Mar 31, 2020 0.24
Dec 31, 2019 0.28
Sep 30, 2019 0.43
Jun 30, 2019 0.53
Mar 31, 2019 0.67
Dec 31, 2018 0.66
Sep 30, 2018 0.66
Jun 30, 2018 0.66
Mar 31, 2018 0.63
Dec 31, 2017 0.62
Sep 30, 2017 0.61
Jun 30, 2017 0.61
Mar 31, 2017 0.60
Dec 31, 2016 0.58
Sep 30, 2016 0.56
Jun 30, 2016 0.54
Mar 31, 2016 0.53
Dec 31, 2015 0.52
Sep 30, 2015 0.52
Jun 30, 2015 0.50
Mar 31, 2015 0.48
Dec 31, 2014 0.47
Sep 30, 2014 0.48
Jun 30, 2014 0.48
Mar 31, 2014 0.45
Dec 31, 2013 0.43
Sep 30, 2013 0.44
Jun 30, 2013 0.44
Mar 31, 2013 0.45
Dec 31, 2012 0.49
Sep 30, 2012 0.56
Jun 30, 2012 0.64
Mar 31, 2012 0.66
Dec 31, 2011 0.65
Sep 30, 2011 0.65
Jun 30, 2011 0.65
Mar 31, 2011 0.64
Dec 31, 2009 0.61
Sep 30, 2009 0.53